Is NRXS or SGHT more profitable?

Sight Sciences has a net margin of -46.83% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat Sight Sciences' return on equity. Company Net Margins Return on Equity Return on Assets NeurAxis -492.76% N/A -641.25% Sight Sciences -46.83% -52.34% -28.49%

Does the media prefer NRXS or SGHT?

In the previous week, Sight Sciences had 5 more articles in the media than NeurAxis. MarketBeat recorded 7 mentions for Sight Sciences and 2 mentions for NeurAxis. NeurAxis' average media sentiment score of 0.99 beat Sight Sciences' score of 0.48 indicating that NeurAxis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeurAxis 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sight Sciences 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is TLSI or NRXS more profitable?

TriSalus Life Sciences has a net margin of -60.85% compared to NeurAxis' net margin of -492.76%. Company Net Margins Return on Equity Return on Assets TriSalus Life Sciences -60.85% N/A -69.91% NeurAxis -492.76% N/A -641.25%

Does the media refer more to TLSI or NRXS?

In the previous week, TriSalus Life Sciences and TriSalus Life Sciences both had 2 articles in the media. NeurAxis' average media sentiment score of 0.99 beat TriSalus Life Sciences' score of 0.00 indicating that NeurAxis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TriSalus Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NeurAxis 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is NRXS or PROF more profitable?

Profound Medical has a net margin of -206.76% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat Profound Medical's return on equity. Company Net Margins Return on Equity Return on Assets NeurAxis -492.76% N/A -641.25% Profound Medical -206.76% -78.88% -64.06%

Does the media prefer NRXS or PROF?

In the previous week, NeurAxis had 1 more articles in the media than Profound Medical. MarketBeat recorded 2 mentions for NeurAxis and 1 mentions for Profound Medical. NeurAxis' average media sentiment score of 0.99 beat Profound Medical's score of 0.00 indicating that NeurAxis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeurAxis 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Profound Medical 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer TMCI or NRXS?

In the previous week, Treace Medical Concepts and Treace Medical Concepts both had 2 articles in the media. NeurAxis' average media sentiment score of 0.99 beat Treace Medical Concepts' score of 0.00 indicating that NeurAxis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Treace Medical Concepts 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NeurAxis 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, NRXS or RXST?

NeurAxis has higher earnings, but lower revenue than RxSight. NeurAxis is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NeurAxis $4.28M 19.79 -$14.63M -$0.81 N/A RxSight $134.48M 1.94 -$38.94M -$1.13 N/A

Is NRXS or RXST more profitable?

RxSight has a net margin of -36.58% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat RxSight's return on equity. Company Net Margins Return on Equity Return on Assets NeurAxis -492.76% N/A -641.25% RxSight -36.58% -17.01% -15.12%

Does the media prefer NRXS or RXST?

In the previous week, RxSight had 4 more articles in the media than NeurAxis. MarketBeat recorded 6 mentions for RxSight and 2 mentions for NeurAxis. NeurAxis' average media sentiment score of 0.99 beat RxSight's score of 0.58 indicating that NeurAxis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeurAxis 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive RxSight 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

NeurAxis (NRXS) Competitors

$6.79 -0.22 (-3.14%)

Closing price 04:00 PM Eastern

Extended Trading

$6.82 +0.04 (+0.52%)

As of 06:29 PM Eastern

Compare

NRXS vs. SGHT, TLSI, PROF, TMCI, and RXST

Should you buy NeurAxis stock or one of its competitors? MarketBeat compares NeurAxis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NeurAxis include Sight Sciences (SGHT), TriSalus Life Sciences (TLSI), Profound Medical (PROF), Treace Medical Concepts (TMCI), and RxSight (RXST).

How does NeurAxis compare to Sight Sciences?

NeurAxis (NASDAQ:NRXS) and Sight Sciences (NASDAQ:SGHT) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership.

In the previous week, Sight Sciences had 5 more articles in the media than NeurAxis. MarketBeat recorded 7 mentions for Sight Sciences and 2 mentions for NeurAxis. NeurAxis' average media sentiment score of 0.99 beat Sight Sciences' score of 0.48 indicating that NeurAxis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeurAxis	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sight Sciences	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sight Sciences has a net margin of -46.83% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat Sight Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeurAxis	-492.76%	N/A	-641.25%
Sight Sciences	-46.83%	-52.34%	-28.49%

NeurAxis has a beta of 1.43, suggesting that its share price is 43% more volatile than the broader market. Comparatively, Sight Sciences has a beta of 2.38, suggesting that its share price is 138% more volatile than the broader market.

11.8% of NeurAxis shares are held by institutional investors. Comparatively, 55.5% of Sight Sciences shares are held by institutional investors. 21.1% of NeurAxis shares are held by company insiders. Comparatively, 30.4% of Sight Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

NeurAxis has higher earnings, but lower revenue than Sight Sciences. NeurAxis is trading at a lower price-to-earnings ratio than Sight Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeurAxis	$4.28M	19.79	-$14.63M	-$0.81	N/A
Sight Sciences	$77.36M	3.90	-$38.43M	-$0.71	N/A

NeurAxis presently has a consensus target price of $13.00, suggesting a potential upside of 91.46%. Sight Sciences has a consensus target price of $7.75, suggesting a potential upside of 39.64%. Given NeurAxis' stronger consensus rating and higher probable upside, equities analysts plainly believe NeurAxis is more favorable than Sight Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeurAxis	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Sight Sciences	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44

Summary

Sight Sciences beats NeurAxis on 9 of the 16 factors compared between the two stocks.

How does NeurAxis compare to TriSalus Life Sciences?

TriSalus Life Sciences (NASDAQ:TLSI) and NeurAxis (NASDAQ:NRXS) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and institutional ownership.

TriSalus Life Sciences presently has a consensus target price of $7.50, suggesting a potential upside of 62.34%. NeurAxis has a consensus target price of $13.00, suggesting a potential upside of 91.46%. Given NeurAxis' stronger consensus rating and higher probable upside, analysts clearly believe NeurAxis is more favorable than TriSalus Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TriSalus Life Sciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
NeurAxis	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, TriSalus Life Sciences and TriSalus Life Sciences both had 2 articles in the media. NeurAxis' average media sentiment score of 0.99 beat TriSalus Life Sciences' score of 0.00 indicating that NeurAxis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TriSalus Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NeurAxis	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TriSalus Life Sciences has a net margin of -60.85% compared to NeurAxis' net margin of -492.76%.

Company	Net Margins	Return on Equity	Return on Assets
TriSalus Life Sciences	-60.85%	N/A	-69.91%
NeurAxis	-492.76%	N/A	-641.25%

NeurAxis has lower revenue, but higher earnings than TriSalus Life Sciences. NeurAxis is trading at a lower price-to-earnings ratio than TriSalus Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TriSalus Life Sciences	$45.15M	6.28	-$39.23M	-$1.41	N/A
NeurAxis	$4.28M	19.79	-$14.63M	-$0.81	N/A

TriSalus Life Sciences has a beta of 0.43, meaning that its share price is 57% less volatile than the broader market. Comparatively, NeurAxis has a beta of 1.43, meaning that its share price is 43% more volatile than the broader market.

2.6% of TriSalus Life Sciences shares are held by institutional investors. Comparatively, 11.8% of NeurAxis shares are held by institutional investors. 16.3% of TriSalus Life Sciences shares are held by insiders. Comparatively, 21.1% of NeurAxis shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

NeurAxis beats TriSalus Life Sciences on 9 of the 14 factors compared between the two stocks.

How does NeurAxis compare to Profound Medical?

NeurAxis (NASDAQ:NRXS) and Profound Medical (NASDAQ:PROF) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, media sentiment, profitability and earnings.

In the previous week, NeurAxis had 1 more articles in the media than Profound Medical. MarketBeat recorded 2 mentions for NeurAxis and 1 mentions for Profound Medical. NeurAxis' average media sentiment score of 0.99 beat Profound Medical's score of 0.00 indicating that NeurAxis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeurAxis	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Profound Medical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

11.8% of NeurAxis shares are held by institutional investors. Comparatively, 47.9% of Profound Medical shares are held by institutional investors. 21.1% of NeurAxis shares are held by company insiders. Comparatively, 1.5% of Profound Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

NeurAxis has a beta of 1.43, indicating that its share price is 43% more volatile than the broader market. Comparatively, Profound Medical has a beta of 0.73, indicating that its share price is 27% less volatile than the broader market.

NeurAxis presently has a consensus target price of $13.00, indicating a potential upside of 91.46%. Profound Medical has a consensus target price of $11.50, indicating a potential upside of 43.93%. Given NeurAxis' stronger consensus rating and higher probable upside, research analysts clearly believe NeurAxis is more favorable than Profound Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeurAxis	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Profound Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Profound Medical has a net margin of -206.76% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat Profound Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeurAxis	-492.76%	N/A	-641.25%
Profound Medical	-206.76%	-78.88%	-64.06%

NeurAxis has higher earnings, but lower revenue than Profound Medical. NeurAxis is trading at a lower price-to-earnings ratio than Profound Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeurAxis	$4.28M	19.79	-$14.63M	-$0.81	N/A
Profound Medical	$16.10M	18.03	-$42.57M	-$1.24	N/A

Summary

NeurAxis beats Profound Medical on 11 of the 16 factors compared between the two stocks.

How does NeurAxis compare to Treace Medical Concepts?

Treace Medical Concepts (NASDAQ:TMCI) and NeurAxis (NASDAQ:NRXS) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, media sentiment, risk, profitability, analyst recommendations and dividends.

Treace Medical Concepts presently has a consensus target price of $4.97, suggesting a potential upside of 3.97%. NeurAxis has a consensus target price of $13.00, suggesting a potential upside of 91.46%. Given NeurAxis' stronger consensus rating and higher possible upside, analysts clearly believe NeurAxis is more favorable than Treace Medical Concepts.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Treace Medical Concepts	2 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.86
NeurAxis	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Treace Medical Concepts and Treace Medical Concepts both had 2 articles in the media. NeurAxis' average media sentiment score of 0.99 beat Treace Medical Concepts' score of 0.00 indicating that NeurAxis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Treace Medical Concepts	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NeurAxis	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

84.1% of Treace Medical Concepts shares are owned by institutional investors. Comparatively, 11.8% of NeurAxis shares are owned by institutional investors. 23.4% of Treace Medical Concepts shares are owned by company insiders. Comparatively, 21.1% of NeurAxis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

NeurAxis has lower revenue, but higher earnings than Treace Medical Concepts. NeurAxis is trading at a lower price-to-earnings ratio than Treace Medical Concepts, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Treace Medical Concepts	$212.69M	1.46	-$59M	-$0.97	N/A
NeurAxis	$4.28M	19.79	-$14.63M	-$0.81	N/A

Treace Medical Concepts has a beta of 1.37, indicating that its stock price is 37% more volatile than the broader market. Comparatively, NeurAxis has a beta of 1.43, indicating that its stock price is 43% more volatile than the broader market.

Treace Medical Concepts has a net margin of -29.44% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat Treace Medical Concepts' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Treace Medical Concepts	-29.44%	-67.04%	-30.28%
NeurAxis	-492.76%	N/A	-641.25%

Summary

NeurAxis beats Treace Medical Concepts on 9 of the 14 factors compared between the two stocks.

How does NeurAxis compare to RxSight?

NeurAxis (NASDAQ:NRXS) and RxSight (NASDAQ:RXST) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment.

NeurAxis has higher earnings, but lower revenue than RxSight. NeurAxis is trading at a lower price-to-earnings ratio than RxSight, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeurAxis	$4.28M	19.79	-$14.63M	-$0.81	N/A
RxSight	$134.48M	1.94	-$38.94M	-$1.13	N/A

NeurAxis has a beta of 1.43, indicating that its share price is 43% more volatile than the broader market. Comparatively, RxSight has a beta of 1.13, indicating that its share price is 13% more volatile than the broader market.

RxSight has a net margin of -36.58% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat RxSight's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeurAxis	-492.76%	N/A	-641.25%
RxSight	-36.58%	-17.01%	-15.12%

NeurAxis currently has a consensus target price of $13.00, suggesting a potential upside of 91.46%. RxSight has a consensus target price of $8.50, suggesting a potential upside of 35.14%. Given NeurAxis' stronger consensus rating and higher possible upside, equities research analysts clearly believe NeurAxis is more favorable than RxSight.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeurAxis	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
RxSight	3 Sell rating(s)	7 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.92

In the previous week, RxSight had 4 more articles in the media than NeurAxis. MarketBeat recorded 6 mentions for RxSight and 2 mentions for NeurAxis. NeurAxis' average media sentiment score of 0.99 beat RxSight's score of 0.58 indicating that NeurAxis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeurAxis	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
RxSight	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

11.8% of NeurAxis shares are owned by institutional investors. Comparatively, 78.8% of RxSight shares are owned by institutional investors. 21.1% of NeurAxis shares are owned by company insiders. Comparatively, 10.1% of RxSight shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

NeurAxis beats RxSight on 10 of the 16 factors compared between the two stocks.

Get NeurAxis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NRXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NRXS vs. The Competition

Export

Metric	NeurAxis	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$84.72M	$5.65B	$6.90B	$12.86B
Dividend Yield	N/A	1.78%	2.60%	10.00%
P/E Ratio	-3.69	23.39	280.82	25.41
Price / Sales	19.79	43.83	599.65	90.78
Price / Cash	N/A	32.60	72.11	49.40
Price / Book	-25.15	6.03	12.95	6.08
Net Income	-$14.63M	$151.74M	$3.49B	$348.07M
7 Day Performance	12.42%	4.81%	3.57%	4.71%
1 Month Performance	-3.82%	-0.15%	-2.50%	-2.12%
1 Year Performance	168.27%	8.50%	73.94%	20.58%

NeurAxis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NRXS NeurAxis	2.2067 of 5 stars	$6.79 -3.1%	$13.00 +91.5%	+178.2%	$84.72M	$4.28M	N/A	19	News Coverage Upcoming Earnings
SGHT Sight Sciences	3.0641 of 5 stars	$5.34 +0.8%	$7.75 +45.1%	+62.5%	$288.37M	$77.36M	N/A	210	News Coverage Earnings Report
TLSI TriSalus Life Sciences	1.849 of 5 stars	$4.38 +1.2%	$7.50 +71.2%	+12.9%	$265.93M	$45.15M	N/A	106	Upcoming Earnings
PROF Profound Medical	1.928 of 5 stars	$7.24 -0.1%	$11.50 +58.8%	+48.4%	$263.47M	$16.10M	N/A	150	Upcoming Earnings High Trading Volume
TMCI Treace Medical Concepts	1.2351 of 5 stars	$4.04 +0.7%	$4.97 +23.0%	-15.5%	$260.14M	$212.69M	N/A	250	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NRXS) was last updated on 8/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NeurAxis (NRXS) Competitors

NRXS vs. SGHT, TLSI, PROF, TMCI, and RXST

How does NeurAxis compare to Sight Sciences?

Summary

How does NeurAxis compare to TriSalus Life Sciences?

Summary

How does NeurAxis compare to Profound Medical?

Summary

How does NeurAxis compare to Treace Medical Concepts?

Summary

How does NeurAxis compare to RxSight?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRXS vs. The Competition

NeurAxis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NeurAxis (NRXS) Competitors

NRXS vs. SGHT, TLSI, PROF, TMCI, and RXST

How does NeurAxis compare to Sight Sciences?

Does the media prefer NRXS or SGHT?

Is NRXS or SGHT more profitable?

Which has more risk & volatility, NRXS or SGHT?

Do institutionals & insiders have more ownership in NRXS or SGHT?

Which has higher earnings and valuation, NRXS or SGHT?

Do analysts prefer NRXS or SGHT?

Summary

How does NeurAxis compare to TriSalus Life Sciences?

Do analysts rate TLSI or NRXS?

Does the media refer more to TLSI or NRXS?

Is TLSI or NRXS more profitable?

Which has stronger valuation & earnings, TLSI or NRXS?

Which has more risk & volatility, TLSI or NRXS?

Do institutionals and insiders hold more shares of TLSI or NRXS?

Summary

How does NeurAxis compare to Profound Medical?

Does the media prefer NRXS or PROF?

Do insiders & institutionals believe in NRXS or PROF?

Which has more volatility and risk, NRXS or PROF?

Do analysts prefer NRXS or PROF?

Is NRXS or PROF more profitable?

Which has better earnings & valuation, NRXS or PROF?

Summary

How does NeurAxis compare to Treace Medical Concepts?

Do analysts rate TMCI or NRXS?

Does the media prefer TMCI or NRXS?

Do insiders & institutionals hold more shares of TMCI or NRXS?

Which has stronger valuation & earnings, TMCI or NRXS?

Which has more volatility & risk, TMCI or NRXS?

Is TMCI or NRXS more profitable?

Summary

How does NeurAxis compare to RxSight?

Which has better earnings and valuation, NRXS or RXST?

Which has more volatility & risk, NRXS or RXST?

Is NRXS or RXST more profitable?

Do analysts rate NRXS or RXST?

Does the media prefer NRXS or RXST?

Do insiders & institutionals have more ownership in NRXS or RXST?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NRXS vs. The Competition

NeurAxis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools